Fig. 2

The presence of 134/144 bp dominant samples was independent of the tumor cfDNA purity. a Pooled insert size distribution of 134/144 bp dominant cfDNA samples from solid tumor patients (n = 35), 166 bp dominant cfDNA samples from solid tumor patients (n = 35, randomly selected from 5608), and cfDNA samples from healthy controls (n = 5). b cfDNA size ratios (100–150 bp/163–169 bp) showed poor correlation with the MSAF within the 35,134/144 bp dominant and the 35,166 bp dominant cfDNA samples. Spearman correlation ρ was labelled on the top right corner of the Fig. c No statistically significant difference (t-test, two-tailed) was observed between the tumor cfDNA purity of 35,134/144 bp dominant and the 35,166 bp dominant cfDNA samples estimated based on the CNV profile. d Tumor cfDNA estimation based on MSAF and CNV profile showed minimal correlation